7.18
+0.14(+1.99%)
Currency In USD
| Previous Close | 7.04 |
| Open | 7.02 |
| Day High | 7.5 |
| Day Low | 6.96 |
| 52-Week High | 54.95 |
| 52-Week Low | 5.01 |
| Volume | 13,725 |
| Average Volume | 42,353 |
| Market Cap | 4.22M |
| PE | 0.01 |
| EPS | 958.65 |
| Moving Average 50 Days | 7.5 |
| Moving Average 200 Days | 10.42 |
| Change | 0.14 |
If you invested $1000 in Quoin Pharmaceuticals, Ltd. (QNRX) since IPO date, it would be worth $0.45 as of September 30, 2025 at a share price of $7.18. Whereas If you bought $1000 worth of Quoin Pharmaceuticals, Ltd. (QNRX) shares 5 years ago, it would be worth $5.7 as of September 30, 2025 at a share price of $7.18.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Quoin Pharmaceuticals Releases Fifth NETHERTON NOW Video Featuring Writers and Influencers Allie and Kaleigh Fasanella, Twin Sisters Living with Netherton Syndrome
GlobeNewswire Inc.
Sep 09, 2025 12:30 PM GMT
New Episode Highlights the Social and Emotional Impact of Netherton Syndrome, the Importance of Supportive Communities, and the Urgent Need for an Approved TreatmentASHBURN, Va., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ
Quoin Pharmaceuticals’ NETHERTON NOW Campaign Surpasses One Million Video Views, Amplifying Global Awareness of Netherton Syndrome
GlobeNewswire Inc.
Aug 21, 2025 12:30 PM GMT
ASHBURN, Va., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that its NETHERTON NOW awar
Quoin Pharmaceuticals Appoints New Chief Financial Officer to Support Commercialization Strategy
GlobeNewswire Inc.
Aug 18, 2025 12:30 PM GMT
ASHBURN, Va., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical stage specialty pharmaceutical company focused on rare and orphan diseases, today announced the appointment of its